emtricitabine (Emtriva, FTC)

Introduction

Tradename: Emtriva

Indications

HIV, chronic hepatitis B

Dosage

200 mg PO QD

Dosage adjustment in renal failure

• dosage reduction if creatinine clearance < 50 mL/min

Pharmacokinetics

• hepatic oxidation & glucuronidation
• cyt P450 system not involved
• clearance 86% renal, 14% fecal
• 2/1life 10 hours

Adverse effects

• well tolerated
• hyperpigmentation on palms & soles (Blacks) 2%
• diarrhea, headache, nausea, rash 1%

• drug adverse effects of antiretroviral agents

Drug interactions

unlikely

• drug interaction(s) of antibiotics with warfarin

Mechanism of action

• inhibits viral reverse transcriptase
• has activity against hepatitis B virus

More general terms

• nucleoside reverse transcriptase inhibitor (NRTI)

Component of

• cobicistat/darunavir/emtricitabine/tenofovir
• bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy, Symtuza)
• cobicistat/elvitegravir/emtricitabine/tenofovir (Quad, Stribild, Genvoya)
• emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF, TAF/FTC/RPV, Complera, Odefsey)
• emtricitabine/tenofovir (Truvada, TDF/FTC, Descovy)
• efavirenz/emtricitabine/tenofovir (Atripla)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60877